XML 52 R41.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Collaborations - Additional Information (Detail) - USD ($) |  | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | ---
May 08, 2020 | Jun. 30, 2022 | Jan. 31, 2020 | Dec. 31, 2018 | Sep. 30, 2022 | Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  | $ 803,000 |  | $ 20,352,000 | $ 12,377,000 | $ 52,754,000
Deferred revenue, recognized |  |  |  |  |  |  |  | 200,000 |
Mosaic Biosciences Inc | Maximum |  |  |  |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Milestone payment related to regulatory and clinical development events | $ 4,000,000.0 |  |  |  |  |  |  |  |
ISU Abxis | Amended and Restated License Agreement |  |  |  |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Regulatory and development milestone payment |  |  |  | $ 2,500,000 |  |  |  | 0 |
ISU Abxis | Maximum | Amended and Restated License Agreement |  |  |  |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  | 19,500,000 |  |  |  | 0 |
Commercial milestone payments |  |  |  | $ 17,000,000.0 |  |  |  | 0 |
Biogen | Collaboration |  |  |  |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  | $ 0.0 |  | $ 1,900,000 | $ 700,000 | $ 4,300,000
Biogen | Exclusive License |  |  |  |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Up-front payments received |  |  | $ 15,000,000.0 |  |  |  |  |  |
Biogen | Termination Agreement |  |  |  |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Forgiveness of accounts receivable, net |  | $ 600,000 |  |  |  | $ 600,000 |  |  |
Payments to cash |  | $ 10,000 |  |  |  |  |  |  |
Biogen | Termination Agreement | General and Administrative |  |  |  |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Settlement expense |  |  |  |  |  | $ 600,000 |  |  |
Biogen | Maximum | Exclusive License |  |  |  |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Development and sales milestone payments |  |  | $ 340,000,000.0 |  |  |  |  |  |

X
- Definition Commercial milestone payments. + References No definition available. + Details
Name: | cbio_CommercialMilestonePayments
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development and sales milestone payments. + References No definition available. + Details
Name: | cbio_DevelopmentAndSalesMilestonePayments
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Forgiveness of accounts receivable, net. + References No definition available. + Details
Name: | cbio_ForgivenessOfAccountsReceivableNet
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payment . + References No definition available. + Details
Name: | cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | cbio_MilestonePayments
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments to cash. + References No definition available. + Details
Name: | cbio_PaymentsToCash
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Regulatory and development milestone payment. + References No definition available. + Details
Name: | cbio_RegulatoryAndDevelopmentMilestonePayment
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Settlement expense. + References No definition available. + Details
Name: | cbio_SettlementExpense
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_MosaicBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_IsuAbxisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=cbio_AmendedAndRestatedLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_BiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=cbio_ExclusiveLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=cbio_TerminationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |